Key result
Liver transplantation fails to prevent arrhythmias requiring pacemaker insertion in familial amyloidotic polyneuropathy.
Why the study?
Only a few studies have analyzed the development of arrhythmia in transplant patients with familial amyloidotic polyneuropathy (FAP).
Does liver transplantation prevent the development of arrhythmia requiring pacemaker insertion in patients with familial amyloidotic polyneuropathy?
Cohort (n=104)
Does liver transplantation prevent the development of arrhythmia requiring pacemaker insertion in patients with familial amyloidotic polyneuropathy?
Liver transplantation does not prevent the continuous development of heart arrhythmia necessitating pacemaker insertion in patients with familial amyloidotic polyneuropathy.
Answers are grounded in this paper and cite their sources.
Ongoing arrhythmia surveillance is warranted after liver transplantation in familial amyloidotic polyneuropathy; this cohort study leaves open whether transplant modifies cardiac progression.
In patients with familial amyloidotic polyneuropathy (FAP), heart complications are prognostic factors for mortality and morbidity after liver transplantation (LT). However, only a few studies have analyzed the development of arrhythmia in transplant patients with FAP. We investigated the development of arrhythmia requiring pacemaker insertion (PMI) in Swedish transplant patients with FAP, and we related the findings to gender, age at disease onset, and survival. One hundred four transplant patients with the amyloidogenic transthyretin Val30Met mutation were included in the study. Twenty-six (25%) received a pacemaker during the observation period (a median of 11 years after disease onset). This frequency was comparable to that noted in a previous study describing the natural course of FAP. No significant differences in PMI between early-onset cases (<50 years old) and late-onset cases (≥ 50 years old) or between genders were observed. PMI was not significantly related to patient survival. Our study confirms our previously reported short-time observation: LT does not prevent the development of heart arrhythmia necessitating PMI. The development of arrhythmia is unrelated to gender or age at disease onset, and the yearly risk does not appear to decrease with time after LT.
No takes yet. Share an insight, caveat, or question.
Okamoto et al. (2010) conducted a cohort in Familial amyloidotic polyneuropathy (FAP) (n=104). Liver transplantation was evaluated on Development of arrhythmia requiring pacemaker insertion (PMI). Liver transplantation did not prevent heart arrhythmia requiring pacemaker insertion, which occurred in 25% (26 of 104) of patients with familial amyloidotic polyneuropathy over a median of 11 years.
Synapse has enriched 10 related papers. Consider them for comparative context: